Clyde Publishes Excitation-Coupling Data
Clyde Biosciences is the leading in vitro cardiomyocyte safety provider with a track record in developing fully validated safety assays to help solve industry wide challenges regarding cardiovascular liabilities beyond that of hERG. Working with the FDA and large pharmas, Clyde has been instrumental in developing next generation assays for pro arrhythmic risk (CiPA Assay) and negative inotropy (CRACKIT).
This publication in the Journal of Cardiovascular Pharmacology highlights our excitation-coupling assay for the parallel assessment of voltage and contractility effects using hiPSC cardiomyocytes. The assay provides a comprehensive set of data on the relationship a drug has on the excitation-coupling mechanism, helping to identify a far broader set of cardiovascular liabilities usually detected at the in vivo stage.
The assay uses Clyde’s 96-well CellOPTIQ platform and can generate results within 5 working days.
The publication can be found at